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Genomic and transcriptomic changes complement
each other in the pathogenesis of sporadic Burkitt
lymphoma
Cristina López et al.#
Burkitt lymphoma (BL) is the most common B-cell lymphoma in children. Within the Inter-
national Cancer Genome Consortium (ICGC), we performed whole genome and tran-
scriptome sequencing of 39 sporadic BL. Here, we unravel interaction of structural,
mutational, and transcriptional changes, which contribute to MYC oncogene dysregulation
together with the pathognomonic IG-MYC translocation. Moreover, by mapping IGH trans-
location breakpoints, we provide evidence that the precursor of at least a subset of BL is a B-
cell poised to express IGHA. We describe the landscape of mutations, structural variants, and
mutational processes, and identiﬁed a series of driver genes in the pathogenesis of BL, which
can be targeted by various mechanisms, including IG-non MYC translocations, germline and
somatic mutations, fusion transcripts, and alternative splicing.
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Burkitt lymphoma (BL), including its leukemic counterpartBurkitt leukemia (B-AL), is a highly aggressive lymphoidneoplasm supposed to derive from germinal center B
(GCB) cells1. It is the most common B-cell lymphoma in children
but also occurs in adults2,3. The monomorphic medium-sized
tumor cells express membrane IgM with light-chain restriction
and typical B-cell antigens, including CD19, CD20, and BCL61.
Three epidemiologic variants of BL are distinguished: endemic,
sporadic, and immunodeﬁciency associated1. Endemic BL is the
predominant form around the malaria belt in Africa. It frequently
involves jaw and facial bone, and is closely linked to Epstein-Barr
virus (EBV) infection4. Immunodeﬁciency-associated BL is rela-
ted with inborn or acquired types of immune deﬁciency. It pre-
sents frequently as nodal disease and EBV infection is
documented in 25–40% of patients5,6. Sporadic BL (sBL), is the
most common form of BL outside the malaria belt. It presents
mostly as an abdominal disease particularly in the ileocecal region
or in lymph nodes. Leukemic inﬁltration accompanies tumorous
presentation in a subset of sBL. Nevertheless, the term B-AL is
restricted to cases with leukemic inﬁltration exceeding 25% of
cells in the bone marrow1. EBV is found in 10 to 20% of sBL.
The genetic hallmark of all three BL types is the IG-MYC
translocation involving the MYC oncogene and mostly the
immunoglobulin heavy chain (IGH) locus, or more rarely, one of
the immunoglobulin (IG) light-chain loci6–8. Subsequent dysre-
gulation of MYC expression has been shown to be driven by the
respective IG enhancer9.
Studies in mice and humans have shown that deregulation of
MYC alone is not sufﬁcient to drive BL lymphomagenesis10–12.
Cytogenetically, BL shows a low genomic complexity, with the
IG-MYC translocation being the sole abnormality in around 40%
of cases7,13,14. Nevertheless, recent sequencing studies identiﬁed
recurrent somatic mutations in ID3, TCF3, CCND3, and
SMARCA4 in both, sporadic and endemic BL15–18. However,
these studies mostly applied exome, transcriptome, or targeted
sequencing strategies, neither taking into account the non-coding
genome nor systematically integrating the various layers of
nucleic-acid encoded information. Investigating a limited set of
13 BL for epigenetic changes, we recently provided initial evi-
dence for a tight connection between somatic mutation, DNA
methylation, and transcriptional control in BL19. Here, in the
framework of the International Cancer Genome Consortium
(ICGC), we performed a comprehensive analysis of whole gen-
ome (WGS) and transcriptome (RNA-seq) sequencing data and
extended our prior series to 39 sBL in children treated in pro-
spective clinical trials. By integration of the different datasets we
provide insights into the complex genomic and transcriptomic
changes underlying MYC dysregulation, the potential cell of
origin of sBL, and the complementarity of mutational mechan-
isms deregulating key pathways in BL.
Results
Study cohort. Using the inclusion criteria outlined in Supple-
mentary Fig. 1a and the Method section, we included a total of 39
IG-MYC single hit (i.e., without a further translocation
event affecting BCL2 and/or BCL6), EBV/HIV negative sBL from
children (≤ 18 years) with a median age at diagnosis of 8 years
(range 2–18) into this study. The male:female ratio in our cohort
is 6.5:1. All patients were registered in one of the clinical trials of
the Mature B-cell-non-Hodgkin-Lymphoma, Berlin-Frankfurt-
Münster (NHL-BFM) study group. At last follow-up (median
time: 67 months), 37 patients were alive without evidence of
disease. The clinical parameters of the 39 patients were com-
parable to the overall B-NHL population treated according to the
Berlin‐Frankfurt‐Münster (BFM) multicenter protocols20 (Sup-
plementary Table 1).
Considering the arbitrariness of the 25% cut-off for distin-
guishing B-AL from BL according to the World health
Organization (WHO) classiﬁcation1, and given that the percen-
tage of bone marrow inﬁltration can vary according to site of
aspirate within a patient, we refrained from differentiating B-AL
from BL. Instead, we classiﬁed the cases according to the site
where the lymphoma cells were derived from for sequencing.
Thus, we distinguished solid manifestation of BL, e.g., in lymph
nodes or solid masses (solBL, n= 27), from non-solid BL forms;
the latter including leukemic manifestations in bone marrow
(leukBL, n= 9), and ﬂuidic manifestation in pleura (pleuraBL, n
= 3) (Supplementary Fig. 1a and Supplementary Data 1).
Molecular classiﬁcation of BL by transcriptional proﬁling. To
conﬁrm the diagnosis of BL on the molecular level, we adapted the
previously published molecular BL (mBL) gene expression index21
to RNA-seq data available for 23 of the 39 patients (16 BL cases
without suitable RNA). For RNA-seq, a median of 138 million reads
(range 95–178 million) were obtained per sample, of which 99.76%
mapped to the human genome (Supplementary Data 2). All
20 solBLs with RNA-seq data were classiﬁed as mBL. However, two
of three leukBL were classiﬁed as non-mBL and all three leukBL
showed an expression pattern more typical for non-mBL for the
majority of genes in the mBL classiﬁer (Supplementary Fig. 1b).
This is in line with our previous ﬁndings using the array-based
classiﬁer and most likely due to the fact that the “mBL index” was
developed to classify BL in solid masses like lymph nodes21. Given
these ﬁndings, we focused only on the solBL cases for all further
expression analyses using the RNA-seq data.
Frequency of genomic alterations determined by WGS. We
performed WGS of tumor and matched normal tissues of all 39
patients with a mean coverage of 38x and 40x, respectively, and
detected overall 98,914 somatic single-nucleotide variants (SNVs)
cohort-wide, corresponding to a median of 2304 somatic SNVs
per sample (range 1178–5279) (Supplementary Fig. 1c). A total of
1238 (1.25%) were predicted to affect protein function, with a
median of 29 per sample (range 16–61). A total of 8214 somatic
small insertions/deletions (indels) were detected, corresponding
to a median of 218 somatic indels per sample (range 75–601), of
which 98 were detected in coding regions, with a median of three
coding indels per case (range 1–8). We investigated the aberra-
tions across the BL groups, and observed a signiﬁcantly lower
number of total coding and total non-coding events in leukBL as
compared to solBL (24 vs 35, p= 0.008, and 1901 vs 2568, p=
0.002, respectively, Kruskal–Wallis Test), and as compared to
pleuraBL (24 vs 32, p= 0.050, and 1901 vs 2954, p= 0.021,
Kruskal–Wallis Test) (Supplementary Fig. 2). A median of 24
high-conﬁdence structural variants (SVs) were found per case
(range 7–289) including a median of eight deletions (range
2–274), two duplications (range 0–12), four inversions (range
0–89), and three translocations (range 0–14, please note that
some IG-MYC translocations were not considered as they had
scores <3, i.e., below the high-conﬁdence threshold, please see
Methods section). Given the low number of SVs as compared to
other germinal center derived B-cell lymphomas (GCB-lympho-
mas), we explored the role of telomere content and function in
BL. Though TERT transcripts are highly elevated in BL compared
to normal GCB cells (p < 0.001) the observed increase of telomere
content between tumor cells and the normal GCB cells controls
was not signiﬁcant (Supplementary Fig. 3).
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Characterization of the IG-MYC translocation. We detected the
pathognomonic IG-MYC translocation, in all samples by ﬂuor-
escent in situ hybridization (FISH) and/or WGS (Supplementary
Data 1). Case 4177434 harbored a complex IGH-MYC-ASIC2
translocation, which could only be resolved by the combination of
cytogenetics and sequencing techniques (Supplementary Fig. 4).
An IGH-MYC juxtaposition was detected in 33 BL, an IGK-MYC
in one case and IGL-MYC in ﬁve cases (Supplementary Data 1).
Different processes remodeling the IG loci have been shown to be
involved in the formation of oncogenic IG translocations in B-cell
lymphomas, namely aberrant VDJ recombination, class switch
recombination (CSR) and somatic hypermutation (SHM)9. To
elucidate the mechanisms contributing to the generation of the
IG-MYC translocations in the analyzed BL, we investigated the IG
breakpoints in detail. We could map the exact breakpoint location
at the IGH locus for 32 out of 33 cases with IGH-MYC translo-
cations using WGS. We observed a translocation of MYC to the
IGHM switch region in 12 cases (37.5%), to one of the IGHA
switch regions (IGHA1= 3 and IGHA2= 5 cases) in 8
cases (25%), to IGHG switch regions (IGHG1= 3 and IGHG3=
3 cases) in 6 cases (18.7%), and to the VDJ region in 6 cases
(18.7%). Of the variant IG-MYC translocations, ﬁve involved
IGLJ and IGLV regions, and one the IGKJ5-IGKC intervening
region. Next, we performed a detailed analysis of the junctional
sequences for the potential mechanism resulting in the translo-
cation. This was feasible in 33 cases. Three cases (4127766,
4158769, and 4189998) were excluded because the sequences were
not informative, two (4193278 and 4103570) because it was not
possible to determine the mechanism causing the translocation
(Supplementary Data 3), and ﬁnally case 4177434 with the
complex IGH-MYC-ASIC2 rearrangement has not been con-
sidered for this analysis. Taking into account all three IG loci,
aberrant CSR was the predominant mechanism leading to IG-
MYC translocation (24/33 informative cases, 73%), followed by
SHM involved in 9/33 informative cases (27%). Of the latter, 4
had the IGL loci as MYC partner. Thus, SHM was the underlying
mechanisms resulting in the translocation in 5/28 BL with IGH-
MYC and 4/5 BL with IGL-MYC juxtaposition, respectively.
Remarkably, a misled VDJ recombination as cause of IG-MYC
juxtaposition was not identiﬁed in any case. We also explored the
location of the breakpoints in the IGH locus within solBL, leukBL,
and pleuraBL separately. The leukBL cases displayed only
breakpoints in the switch IGHM or VDJ regions. In contrast,
solBL and pleuraBL showed breakpoints distributed over the
whole IGH locus (Supplementary Fig. 5a). For formal testing of
these different distributions, we classiﬁed the breakpoints into
two groups: centromeric of IGHM (i.e., switch regions upstream
of constant regions involved in later phases of the immune
reaction) and within the IGHM region/or telomeric of IGHM
(including VDJ) (Supplementary Fig. 5a). The location of
breakpoints in the IGH locus differed signiﬁcantly between
leukBL, solBL, and pleuraBL (p= 0.031, Pearson Chi-Square test);
the leukBL showed the breakpoints within or telomeric of the
IGHM region, whereas solBL and pleuraBL displayed breakpoints
distributed over the whole IGH locus. Finally, we extended the
study of the IGH breakpoints to adult GCB-lymphomas other
than BL with break in IGH locus. We included follicular lym-
phoma (FL) (n= 84), diffuse large B-cell lymphoma (DLBCL)(n
= 75) and FL-DLBCL (n= 17), as well as double hit (DH) lym-
phomas (n= 2) with mBL signature and B-cell lymphoma not
otherwise speciﬁed (B-NOS, n= 1) from the ICGC MMML-Seq
project (unpublished data). In this extended cohort we observed a
signiﬁcant skewing of the IGH breakpoints in BL to the IGHA
switch regions (Supplementary Fig. 1a). Indeed, oncogene-IG-
translocations with breakpoints in the IGHA switch region were
only observed in cases with MYC as partner and were almost
exclusive to BL (p < 0.0001) in the complete ICGC MMML-Seq
population (Supplementary Fig. 5b-c). The only exception was a
DH lymphoma with mBL signature presenting in the tonsil of a
75-year-old patient that displayed an IGH-MYC fusion with a
breakpoint in the IGHA1 switch region (case 4182605). We
cannot exclude that this case is indeed also a bona ﬁde BL despite
the DH. Given that CSR is supposed to require transcription22,
we investigated the IGHA RNA expression in relation to the
breakpoint location in the BL cohort. We observed a signiﬁcantly
higher expression of IGHA transcripts in cases with IGH-MYC
translocation breakpoints mapping to the IGHA region (p=
0.0012, Wilcoxon test).
Next, we analyzed the breakpoints of the IGH-MYC fusions on
chromosome 8 (MYC) in more depth. These have previously been
classiﬁed in three categories according to the position of the
chromosomal breakpoints relative to the MYC gene23. We
observed class I breakpoints affecting the ﬁrst exon or intron of
MYC in 17 of 32 cases (53%, case 4177434 with IGH-MYC-ASIC2
rearrangement not considered for this analysis), and class II
breakpoints located immediately upstream of MYC in 14 of 32
(44%) (Supplementary Data 3). No class III breakpoint far
upstream of the 5′ end of the gene was detected. However,
unexpectedly one case with an IGH-MYC translocation, had a
breakpoint downstream of MYC. In contrast to the classic MYC
translocation involving IGH, variant MYC translocations to IGK
and IGL (n= 6 cases), showed breakpoints downstream of MYC
in line with previous studies23,24.
To gain deeper mechanistic insight into the BL hallmark event
we studied the effects of the different IG-MYC translocations on
MYC gene expression (Fig. 1b). High RNA expression of MYC
was observed in BL as compared to normal GCB cells (fold
change 11.78, p < 0.0001, Wilcoxon test, Fig. 1c). MYC transcript
levels were similar in cases with IGH-MYC and with the variant
IGK/IGL-MYC translocations. Furthermore, we investigated
allele-speciﬁc MYC transcript expression using somatic sequence
variants in the transcribed regions as surrogate marker of the
translocated MYC allele (IGH-MYC). We observed that the vast
majority of MYC transcripts originate from the translocated allele
(Fig. 1d). Remarkably, we identiﬁed two different forms of MYC
transcripts that were associated with the location of the
translocation breakpoints. Canonical MYC transcripts mainly
occurred in cases with class II breakpoints, whereas expression of
an alternative MYC transcript using an alternative transcription
start site within the canonical ﬁrst intron was linked to class I
breakpoints (Fig. 1b). The mRNA produced from the alternative
transcript contains 486 nucleotides from this intronic sequence
(chr8: 128750008–128750493 bp, hg19), which are not included
in the canonical transcript. Nevertheless, this alternative tran-
script is predicted to encode the same MYC protein as the
canonical transcript, because the start codon predominantly used
for MYC protein expression in BL is located in exon 2 of the gene
(isoform 1: P-01106–1)25. Moreover, the additional 486 nucleo-
tides do not contain an open reading frame continuing into the
coding sequence in exon 2. Surprisingly, we observed one case
(4125240) exhibiting expression of the ﬁrst exon of MYC,
indicative of the canonical transcript, but also the intronic
sequence, which is part of the alternative transcript. There were
hardly any sequencing reads spanning the splice junction between
the canonical MYC exons 1 and 2 (Supplementary Fig. 6).
Combining data from WGS, RNA-seq, and FISH we were able to
reconstruct a complex genomic event in this case, which
separated exons 2 and 3 (alternative transcript) from exon 1 of
MYC and brought both parts under the inﬂuence of different IGH
enhancer elements (Supplementary Fig. 6a).
Previous studies have identiﬁed BCL6 binding sites (BCL6BS)
in the promoter region of the MYC gene, located within 2 kb
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upstream of the canonical MYC transcription start site (TSS).
BCL6 binding represses MYC transcription in GCB cells26. As BL
cells express BCL6 and, thus, should suppress MYC expression,
we investigated, if the BCL6BS is affected by the translocations
using the genomic coordinates previously described (chr8:
128746338-128748338 bp, hg19)26,27. Indeed, in all 31 BL cases
with IGH-MYC translocation and class I/II breakpoints the
suppressive BCL6 element is either translocated away from the
MYC gene (n= 15) or directly affected (n= 16) by the
breakpoint.
Next, we explored the presence of IGH-MYC fusion tran-
scripts. Fusion reads from the der(14) chromosome were
observed in the RNA-seq data in 9 of 18 evaluable cases (50%).
Remarkably, more than one type of fusion transcript (with
maximum of 4) was detected from both derivative chromosomes
in 5 of 9 cases as consequence of the IGH-MYC translocation. We
could determine the orientation of those fusion transcripts in ﬁve
cases and interestingly all of them appeared to be an antisense
transcript. IGH and MYC antisense transcripts have been
previously described and linked to IGH switch regions and the
SHM and CSR events generated by the enzyme activation-
induced cytidine deaminase (AID)28–30. Thus, the identiﬁed
antisense fusion transcription might be attributed to the
generation of the translocation breakpoints by this enzyme. In
addition, we discovered in four cases fusion transcripts between
IGH sequences on der(8) and the lncRNA CASC11. This lncRNA
is located ~2 kb upstream of MYC and transcribed in the same
orientation as the IGH locus on der(8) but in opposite direction
to MYC. As expected, all cases with IGH-CASC11 fusion
transcripts exhibited breakpoints upstream of MYC (class II).
Overall, we found that MYC transcription is mainly driven
from the translocated allele, on which the BCL6BS suppressive
element is either translocated away or disrupted, and that class I
breakpoints lead to expression of an alternative MYC transcript.
Moreover, associated with t(8;14) we observed IGH-MYC fusion
transcripts in some of the cases. Furthermore, we detected IGH-
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Fig. 1 Integrative analysis of the IG-MYC translocation. a Forest plot comparing breakpoint occurrences in the switch region of the IGH locus between BL
cases (39 BL studied herein and additional one adult BL) and 179 non-BL GCB-lymphomas, showing a statistically signiﬁcant enrichment of breakpoints in
the switch IGHA regions in BL (Fisher test). b Distribution of somatic SNVs and breakpoints (Class I and II) in the MYC locus in cases with IGH-MYC
translocations correlated with the expression pattern of the MYC transcript (upper panel: canonical transcript; lower panel: alternative transcript). Cases
with breakpoints downstream of MYC and/or without available RNA-Seq data are not shown. The genomic coordinates (hg19) on chromosomal region
8q24 are given as x axis on the top. Blue arrows inMYC gene indicate the transcriptional orientation on the forward strand. The scale of the y axis indicates
the mean expression of the respective MYC transcript across the cases using a maximum scale of 55 (normalized value of the expression). Note that due
to the resolution not all neighboring mutations can be clearly distinguished. cMean expression of MYC transcripts in normal germinal center B-cells from 5
donors (control) (black) and BL cases with the typical IGH-MYC translocation (n= 18) (dark gray) or its variants, IGK- or IGL-MYC (n= 5) (light gray). d A
predominant expression of the translocated allele, irrespectively of canonical or alternative transcript, is determined by allele-speciﬁc expression analysis of
MYC by comparing the fraction of translocated allele vs the total MYC allele expression in each group of the BL cohort. The box plots give the range of the
fractions (per somatic SNV) of translocated allele vs total MYC expression per case
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CASC11 fusion transcripts, which have not been previously
described.
Analysis of MYC SNVs and indels. Besides genomic transloca-
tion, dysregulation of MYC can also be caused by SNVs and
indels15,17. Occurrence of multiple nonsynonymous mutations in
the coding sequence of the MYC gene have been described in
approximately 40–70% of BLs15,17. These SNVs cluster in the
MYC transactivation domain with hotspots in the Myc box I
(MBI) motif (44–63aa)15,17. In our cohort, we identiﬁed a total of
370 coding and non-coding SNVs in the MYC locus
(ENST00000377970.2, Fig. 1b). Of these, 184 occurred in cases
expressing the canonical and 30 in cases expressing the alternative
MYC transcript; the remaining 156 SNVs were in cases where the
transcript could not be classiﬁed, due to the unavailability of
RNA. Of 184 SNVs in cases expressing the canonical transcript, 2
mutations (1%) were located upstream of the transcription start
(16 and 343 bp upstream), 31 (17%) were located in the 5′UTR,
23 (12%) in coding regions (8 in exon 1 and 15 in exon 2), and
128 (70%) in intronic regions (125 in intron 1, and 3 in intron 2)
(Supplementary Data 4, Figs. 1b and 2a). Of the 30 SNVs in cases
expressing the alternative transcript (chr8:
128750008–128750493 bp, hg19), 1 (3.3%) affected the exon 1 of
the canonical transcript, 8 (26.7%) intron 1, and 6 (20%) intron 2.
These, did not affect the overexpressed MYC transcript. A total of
13 (43%) fell into exon 2 with 5 of them affecting the part of exon
2 exclusive to the alternative transcript (Supplementary Data 4).
We also detected 7 small indels in 7 patients, and 7 SVs (3
duplications, 3 deletions, and one inversion) involving MYC in
ﬁve BL; three of them were located in the coding region. In total,
MYC aberrations affecting the exonic coding or splice regions
were observed in 77% (30/39) of the analyzed BL, including 60
SNVs and 3 SVs. A total of 10 exonic positions were recurrently
mutated with 8 of them showing exactly the same base change.
The SNVs and SVs clustered in the transactivation domain,
affecting the conserved boxes MBI and II (11.1%, 7/63 events)
(Fig. 2b). However, a mutational hotspot (6/39 cases; 15%) in our
cohort was outside of MBI at position 149 (p.Leu149Val) in the
protein sequence (P-01106–1) encoded by both canonical and
alternative transcript (corresponding to position 164 for P-
01106–2 isoform, only encoded by the canonical transcript).
Interestingly, the mutations were more frequently located in the
ﬁrst 100 aa (36/58 exonic coding SNVs) than in the rest of the
protein (P-01106–1) (22/58 SNVs) (p < 0.0001, Fisher’s exact
test). This might be of relevance for common diagnostics, because
the immunogen for a widely used antibody (clone Y69) are the
ﬁrst 100aa of the protein. MYC gene mutations were also sig-
niﬁcantly enriched in target motifs of the SHM machinery
(RGYW and DGYW motifs, p < 0.0001 and p < 0.0001, respec-
tively, Fisher’s exact test) (Fig. 2a).
Moreover, the coding mutations clustered signiﬁcantly (p <
0.0001, Fisher´s exact test) around known phosphorylation site
containing regions (using a window of +/− 4 aa positions to
evaluate the presence of mutations in proximity to known
phosphorylation sites) (Fig. 2b). Since phosphorylation is
required for ubiquitination and degradation of the MYC protein
by the proteasome, abolition of phosphorylation could lead to a
decrease of protein degradation and hence, increase the stability
of the MYC protein31.
Thus, besides IG enhancer hijacking through the IGH-MYC
translocations, expression of the alternative MYC transcript as
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well as protein stabilization due to mutations close to phosphor-
ylation regions might be mechanisms to deregulate activity of
MYC in BL.
IG-non-MYC translocations in BL. Whereas the IG-MYC
translocations are pathognomonic for BL, IG-translocations
involving other commonly affected lymphoma oncogenes, in
particular BCL2 or BCL6, are usually absent in BL. Indeed, high-
grade B-cell lymphomas with chromosomal breakpoints affecting
the MYC locus in combination with breakpoints involving the
BCL2 or BCL6 genes, constitute a separate entity frequently called
“DH lymphomas”1. Nevertheless, the existence of IG transloca-
tions to non-MYC partners, which could cooperate with MYC in
the pathogenesis of BL, has not yet been systematically explored.
We discovered in 3/39 cases (8%) IG non-MYC translocations by
WGS: one case each of IGH-CBFA2T3 (4170844, solBL), IGH-
HECW2 (4110498, leukBL), and IGK-CCNG1 (4152036, pleur-
aBL), considering candidate oncogenes in proximity to the
breakpoint on the IG partner chromosomes (Fig. 2a). We vali-
dated all three translocations by PCR and Sanger sequencing
(Supplementary Data 5). The IGH breakpoint of the IGH-
CBFA2T3 translocation mapped to the IGHA1 switch region,
whereas the breakpoint of the corresponding IGH-MYC trans-
location was located in the IGHM switch region. The IGH-
HECW2 translocation had the breakpoint in an IGHG switch
region, whereas the IGH-MYC translocation affected the IGHM
switch region. The IGK-CCNG1 translocation had breakpoints
approximately 350 kb upstream of CCNG1 and in the IGKV
region. Breakpoints in switch regions indicate that CSR was the
mechanism leading to the IGH-CBFA2T3 and IGH-HECW
translocations, and remarkably again IGHA was involved in one
case. It was not possible to determine the timing of the events in
the cases with two IGH breakpoints directly from the sequencing
data due to the short sequencing reads and the distances of the
breakpoint on the IGH locus. However, detailed analysis showed
that the IGK-CCNG1 breakpoint was located exactly at the 3′ end
of an IGKV segment and the breakpoint junction contains
additional nucleotides (Fig. 3b). Such N-nucleotides are added by
the lymphocyte-speciﬁc terminal deoxynucleotidyltransferase
(TdT) during VDJ recombination mediated by the nucleases
RAG1/RAG2. Thus, though rare cases of light-chain revision in
germinal center B-cell lymphomas have been described, this event
more likely occurred in an early stage of B-cell development in
the bone marrow compartment, when the cell attempted to
perform an IGKV to IGKJ recombination32,33. Overall, this
strongly indicates that the IGK-CCNG1 translocation occurred
earlier (at the pre-B or immature B-cell stage) in the evolution of
this tumor than the IGH-MYC translocation (at the germinal
center stage) showing that IG-MYC translocations might not
always be the initial genetic event in BL (Fig. 3c). All partners of
these IG non-MYC translocations have been linked to oncogen-
esis. An IGH-CBFA2T3 translocation has been previously detec-
ted in two patients with pediatric GCB-lymphomas, suggesting
that CBFA2T3 may represent a recurrent oncogene partner of the
IGH locus34. HECW2 is an ubiquitin-protein ligase that mediates
ubiquitination of the tumor suppressor protein TP73, a member
of the p53 family of transcription factors, and also degrades
ATR35. Finally, CCNG1 is a cyclin which is thought to play a role
in growth regulation, participates in p53-dependent G1-S and G2
checkpoints and might function as an oncogenic protein in
ovarian carcinoma36. Unfortunately, we could not analyze the
expression of the new partners due to lack of RNA in those cases.
In summary, oncogenes other than MYC can be activated
through juxtaposition with IG loci in BL, and some of those
events can even precede the IG-MYC translocation.
Fusion transcripts. Besides oncogene activation by enhancer
hijacking as in the case of IG-translocations, the generation of
fusion genes is a common mechanism through which SVs can
contribute to oncogenesis. Combining the data from WGS and
RNA-seq (Supplementary Fig. 7), we identiﬁed 58 intragenic
fusions at the genome level (excluding the IG and MYC loci),
eight of which resulted in detectable fusion transcripts (7 intra-
and 1 inter-chromosomal) (Supplementary Data 5). The affected
genes are involved in key mechanisms of cancerogenesis like
proliferation (TSC22D2 and ZMAT3), NF-κB signaling (BACH2,
MAP3K7, and TRAF3IP2), JAK-STAT signaling (CD109), and
immune system regulation (SOCS5). We validated the GTPBP8:
C3orf17 and CD109:TRAF3IP2 fusions at genomic and tran-
scriptomic levels using PCR and Sanger sequencing. Both vali-
dated fusions exhibited the genomic breakpoints in the introns of
the involved genes (Supplementary Data 5). Interestingly, the
GTPBP8:C3orf17 fusion retained the affected introns of both
genes in the fusion mRNA. We then investigated the presence of
intron retention in all fusion transcripts and identiﬁed two
additional fusion transcripts, SLC8A1:SOCS5 and TSC22D22:
ZMAT3, with evidence of intron retention at the breakpoint
junction. Hence 3/8 fusion transcripts (38%) exhibited intron
retention at the breakpoint junction, suggesting that gene inac-
tivation by intron retention is a common consequence of fusion
gene generation during Burkitt lymphomagenesis.
Alterations in coding genes. In recent years, additional genes
besides MYC have been described as recurrently mutated in BL,
usually as a consequence of point mutations15–17,37. To elucidate
the genes involved in BL lymphomagenesis, we performed an
integrative analysis of the different somatic genomic alterations
potentially resulting in gene deregulation, namely SNVs, indels,
SVs, and copy number aberrations (CNAs). The mean number of
gained or lost regions per case was only 2.05 (range 0–10) and
1.82 (range 0–8), respectively; exhibiting a low number of CNAs
in accordance with previous cytogenetic and array-based analyses
of BL38 (Fig. 4a). Incorporating all data on genomic alterations,
we identiﬁed 49 coding genes affected in at least three cases
(Fig. 4b, c). Eight of these were affected in ≥20% of samples
(MYC, ID3, CCND3, TP53, SMARCA4, FBXO11, ARID1A, and
DDX3X). Selected SNVs and SVs were validated by Sanger
sequencing based on DNA availability (Supplementary Data 5
and 6). Correlating the number of mutations per gene to its
replication timing in lymphoblastoid B-cell lines showed that
many recurrently mutated genes replicate rather early in B-cells
(Fig. 4c). Using IntOGen39, we identiﬁed 18 genes as putative
driver genes in BL (ID3, TP53, CCND3, SMARCA4, FBXO11,
ARID1A, DDX3X, GNA13, FOXO1, RHOA, TCF3, PCBP1, RFX7,
E2F2, GNAI2, TFAP4, ADNP, and HNRNDP). All cases exhibited
mutations in at least one driver gene. In 29/39 cases (74%) we
detected an ID3 and/or TCF3 alteration. Disruption of
Gα13 signaling via mutations in GNA13, ARHGEF1, S1PR2,
RHOA, or P2RY8 has been recently described as a mechanism
involved in survival and local conﬁnement of GCB cells to the
germinal center40. We observed mutual exclusive aberrations of
RHOA (7/39, 18%), P2RY8 (7/39, 18%), and GNA13 (5/39, 13%).
Interestingly, RHOA or P2RY8 alterations were observed only in
solBL (14/27, 52%) but not in any of the 12 non-solid BL.
Alterations in non-coding genes. Recurrent mutations were
detected in six non-coding RNAs, namely RP1–150O5.3 (4/39,
10%), LINC00939 (3/39, 8%), RP11–351J23.2 (3/39, 8%), CASC2
(3/39, 8%), MIR4447 (3/39, 8%), and RNU5E-8P (3/39, 8%)
(Fig. 4b). RP1–150O5.3 is located downstream of the ID3 gene
and both genes are co-deleted in the 4 BL cases. The lncRNA
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cancer susceptibility candidate 2 (CASC2), is recurrently deleted
in solid tumors, suggesting a tumor suppressor function41,42.
Recently, CASC2 was described as being involved in regulation of
the PI3K cascade by inhibition of miR-18a, and in regulation of
the PTEN pathway by inhibition of miR-2143. The RNU5E-8P
(3q13.31), MIR4447 (3q13.31), RP11–351J23.2 (6q27), and
LINC00939 (12q24.32), have to the best of our knowledge not yet
been associated with cancer, though RP11–351J23.2 is located in a
candidate tumor suppressor gene locus in lymphomas identiﬁed
by deletion mapping44.
Mutual exclusivity of gene alterations. To elucidate the role of
mutated genes in BL and detect functional modules, we searched
for mutual exclusivity of alterations among all recurrently affected
coding (n= 49) and non-coding genes (n= 6) (Fig. 5a). Aber-
rations of CCND3 rarely co-occurred with those in the tumor
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Fig. 4 Gene dysregulation in BL. a Cumulative imbalance proﬁle of 37/39 BL cases excluding the physiological rearrangement in IGH, IGK, and IGL loci. The
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suppressors LSAMP and TUSC7, and in particular with the
transcription factor RFX7. Mutual exclusivity argues that there
could be a functional connection between RFX7 and CCND3.
Although there is no pathway or discrete gene ontology group
containing both proteins, there is evidence that both share
upstream regulatory genes45 and that they participate in the same
tissue-speciﬁc functional interaction network http://hb.
ﬂatironinstitute.org/gene/896+64864. Moreover, RFX7 (and
other RFX transcription factors) is co-expressed with CCNK, a
regulatory subunit of cyclin dependent kinases46 and RFX7 is
described as transcription factor for the oncogene MYC. Taken
together, these ﬁndings suggest that RFX7 could be a transcrip-
tion factor regulating genes in cell cycle control (including
CCND3). The precise role of this putative cell-cycle related pro-
cess in BL will require additional investigation. On the other
hand, mutations in RFX7 were also to a considerable extent
exclusive to SMARCA4, which in turn showed strong exclusivity
with mutations in yet another member of the SWI/SNF complex,
ARID1A. Alterations in the ID3 gene were mutually exclusive
with alterations of TCF3 and also GAB1, which are all implicated
in tonic BCR signaling47. Remarkably, FOXO1 and MYC muta-
tions were also to a considerable extent exclusive. A mutual
exclusivity between TP53 and CDKN2A alterations has been
previously described in large B-cell lymphomas and BL48, how-
ever, using our approach and considering p-value <0.1 as cut-off
for mutual exclusivity, we did not identify this association in our
series. Manual inspection revealed that indeed, alterations of
TP53 and CDKN2A seem to occur mutually exclusive. Moreover,
the cases exhibiting genomic aberrations in TP53 showed higher
expression of CDNK2A (p-value <0.1) (Supplementary Fig. 7b).
Overall, the integrative analysis revealed that mainly three
interacting biological pathways or complexes are altered in BL:
proliferation and survival, the SWI/SNF complex, and tonic BCR
signaling.
Differential splicing of genes altered in BL. To investigate if BL
exhibit differential splicing as complementary mechanism to
alterations affecting the coding sequence on genome level, we
analyzed differential splicing in 77 genes including all predicted
driver genes, all recurrently (≥3 cases) mutated genes, all new IG
non-MYC translocation partners, and all genes involved in fusion
transcripts identiﬁed in the present study. We compared the
RNA-seq based expression pattern to normal GCB cells and
identiﬁed differential splicing in 40/77 genes (52%). Among those
was TCF3, which showed upregulation of the isoform E47 and
downregulation of E12 in BL as compared to GCB cells (Fig. 6a).
At the genomic level the mutations in TCF3 observed in our
cohort and described previously17,37 are located in the helix-loop-
helix (B-HLH) DNA binding and dimerization domain of the
E47 splice isoform, but remarkably not in the E12 encoding part
of the gene. We correlated the expression of both TCF3 isoforms
to the mutational status of its negative regulator ID3. The relative
expression of the isoform E47 showed a strong trend towards
higher expression (p= 0.08, Wilcoxon rank sum test) in the BL
cases without ID3 mutations (Fig. 6b). The protein isoforms E47
and E12 are predicted to differ in the electrostatic charge of the B-
HLH domain which might affect DNA binding. The isoform E47
contains 4 negatively charged residues less than isoform E12,
showing an overall more positive charge at the DNA-binding
groove (Fig. 7a–c). Thus, increased expression of E47 might
similarly enforce TCF3 binding activity to DNA like inactivating
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its negative regulator ID3 by mutations or introducing activating
mutations in TCF3.
We extended the analysis of the differential expression of the
E47 and E12 TCF3 isoforms to adult GCB-lymphomas other than
BL. To this end, we mined RNA-seq data from FL (n= 85),
DLBCL (n= 72), and FL-DLBCL (n= 17) generated within the
ICGC MMML-Seq consortium using the same sequencing
pipeline (unpublished data). In this non-BL cohort the prefer-
ential usage of the isoform E47 is signiﬁcantly lower than in BL
(BL vs non-BL, p < 0.001) (Supplementary Fig. 8). Given that a
recent study has identiﬁed differential expression of the E12 and
E47 TCF3 isoforms in pluripotent human embryonic stem cells
(ESCs) compared to differentiated cells we extended our analysis
to published data from ESCs and induced pluripotent stem cells
(iPSCs)49,50 (Supplementary Fig. 8). Indeed, we corroborated the
relatively high expression of E12 as compared to a relatively low
expression of E47 in ESCs and iPSCs cells (joined ESCs/iPSCs vs
GCB cells p= 0.002, Wilcoxon rank sum test). Thus, differential
expression of the E47 and E12 TCF3 isoforms seems to be a
common mean to regulate TCF3 function. Skewing towards the
E47 expression seems to be particularly pronounced in BL as
compared to other mature GCB-lymphomas and, thus, likely
contributes to deregulation of the TCF3/ID3 complex particularly
in BL lacking ID3 and/or TCF3 mutations.
Another gene showing signiﬁcant differential splicing in BL as
compared to GCB cells was CBFA2T3. Here, expression of
isoform 2 which lacks amino acids 1–61 and 102–126 of the
canonical form was preferentially expressed in BL. Isoform 2 acts
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as an A-kinase-anchoring protein, interacting with PDE7A and
PRKAR2A51, and thus regulates cAMP-mediated signaling. This
pathway is regulated by GNAS-coupled G-protein coupled
receptors, for which mutations in colorectal cancer have been
shown to activate cAMP signaling52. In order to investigate the
mechanism causing this differential splicing, we mined our
previously published DNA methylation data19, and identiﬁed a
region in CBFA2T3 differentially methylated (DMR) between BL
and GCB cells. DNA methylation of this DMR is negatively
correlated with gene expression of the long transcript (Fig. 8).
Interestingly, this DMR in CBFA2T3 contains a transcription
factor binding site for TCF3 (based on ENCODE data),
suggesting that TCF3 might be involved in the regulation of
alternative splicing of CBFA2T319. Moreover, the IG transloca-
tion associated breakpoints in CBFA2T3 in the case described
above and in another, previously published pediatric mature B-
cell leukemia diagnosed morphologically as B-AL34 disrupts
isoform 1 and should lead to preferential expression of isoform 2.
In acute myeloid leukemia, CBFA2T3 can be a translocation
partner of RUNX1, producing a chimeric protein with break-
points usually between exons 1 and 2, or exons 3 and 4 of
CBFA2T353. TCF3 binds both CBFA2T354 and ID355 likely via
N- and C-terminal regions, respectively56 (Fig. 7a). This suggests
that CBFA2T3, which is dysregulated in BL, via translocation,
differential splicing, and differential methylation, belongs to an
ID3-TCF3-CBFA2T3 network important to Burkitt
lymphomagenesis.
Germline mutations. Several germline mutations predisposing
individuals to particular cancers are known, but to date only few
have been described for BL57. Aiming at clearly damaging
changes we focused on protein-truncating germline mutations in
114 known cancer predisposition genes in the present BL
cohort58. We found such germline mutations in CHEK2 and
FANCG each in one, and two germline mutations in the BLM
gene in another patient. All germline mutations were validated by
PCR and Sanger sequencing (Supplementary Data 6). Although a
predisposing role of the heterozygous FANCG for BL could not
ﬁrmly be established, we consider the changes in CHEK2 and
BLM relevant for the pathogenesis of BL. The frameshift muta-
tion in CHEK2 leads to a truncated protein (p.Thr410Metf-
sTer15). Germline mutations in CHEK2 (OMIM: 604373), in
particular truncating mutations, are considered causative of Li
Fraumeni (like) syndrome 2 (LFS2) (OMIM: 609265) and are
associated with increased cancer risk, with lymphoma belonging
to the disease spectrum of LFS59,60. The BLM mutations were
compound heterozygous, leading to biallelic inactivation. Indeed,
clinical features of the patient were in line with the phenotype of
Bloom syndrome (OMIM: 210900) but the diagnosis was
not made prior to the current study. Individuals with Bloom
Syndrome, which is a rare autosomal recessive disorder char-
acterized by genomic instability, have been described to carry a
higher risk of developing cancers including lymphomas. Taken
together, 2/39 (5%) patients with pediatric BL investigated in this
series carry likely pathogenic germline changes predisposing to
this disease.
In addition to the known cancer predisposition genes we also
investigated the presence of germline mutations in genes showing
somatic alterations in BL. Focusing on the same 77 genes that
were subjected to the differential splicing analysis, we identiﬁed
germline nonsynonymous SNVs, non-frameshift insertions or
splice site mutations in 26 of 77 (34%) genes analyzed (27/39
patients), with frequencies from 3 to 13% (Fig. 9a). We observed
co-occurrence of germline and somatic mutations in the same
gene in two patients, indicating double hits affecting these genes
(FOXO1 and RYR2). After ﬁltering for allele frequency of the
mutations in a public database (gnomAD, 11.09.2017), the impact
of the variants at protein level, the tolerance/intolerance of a gene
towards new functional mutations, and the presence of the
variant in the non-BL cohort from the ICGC MMML-Seq project,
we ended up with 6 germline mutations across 5 genes affecting 6
patients that could be potentially relevant for lymphomagenesis.
The genes affected were NCOR1, CREBBP, RYR2, ARID1A, and
NRXN3.
In total, 72% (28/39) of BL cases exhibited germline mutations
in cancer predisposition genes or/and genes somatically mutated
in BL, indicating a potential crucial contribution of germline
events in BL lymphomagenesis.
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Fig. 7 The ID3-TCF3-CFBA2T3 complex. a Protein structure of TCF3 (green) in complex with ID3 (blue) and bound to DNA (bottom). The N-terminal
region that interacts with CBFA2T3 (orange) is separated by a long disordered/unstructured region (shown as a looped line). b Alignment of the DNA-
binding region (residues 527–644) of TCF3 (Uniprot: P15923). The location of the domain is inferred by sequence similarity to the structure from protein
databank code 2ypa chain A (a heterodimeric complex involving an equivalent domain from human TAL1 in complex with DNA). Differences between the
sequences are highlighted (uncolored and bold for uncharged amino acids; red for negatively charged and blue for positively charged amino acids). Note
that many changes alter the charge in one isoform relative to the other, leading to a net gain of four negative charges in isoform E12 relative to isoform E47.
c Representations of the electrostatic surface of the E12 (left) and E47 (right) isoforms. The surface of E47 has a more positive electrostatic potential
(blue). Also indicated is the loss of four negative (Glu/Asp) residues at the N-terminal portion of the domain, which were not present in the model (as
there was no suitable structural template for them). The loss of these four negative charges also means that the E47 isoform is relatively more positively
charged
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Mutational signatures. Germline mutations in some cancer
predisposing genes have been linked to certain mutational sig-
natures in the tumor cells. To investigate whether the patients
with the BLM and CHEK2 mutations showed particular muta-
tional patterns, we explored the distribution of SNVs over the
genome in all BL. We observed four regions of increased SNV
density in BL with at least ﬁve SNVs with at most 1000 bp
intermutational distance, similar to what has previously been
deﬁned as Kataegis61. These regions were restricted to the MYC
and the three IG loci (Fig. 9b). Remarkably and in contrast to
other GCB-lymphomas we did not identify further regions of
recurrent kataegis. Applying a new mathematical approach for
supervised mutational signature analysis (unpublished data), we
identiﬁed 6 of the 30 previously described signatures (AC1—
spontaneous deamination, age related, 32/39= 82.1% of the
samples affected; AC2—APOBEC, 27/39= 69.2%; AC6—mis-
match repair defects, 39/39= 100%; AC9—mistakes in poly-
merase ŋ 39/39= 100%; AC10—mistakes in polymerase ɛ,
38/39= 97.4%; and AC17—mechanism unknown, 28/39=
71.8%)62,63 (Fig. 9c). Furthermore, we identiﬁed contribution by
three new mutational signatures (L1–39/39= 100%, L2–38/39=
97.4%, and L3–16/39= 41.03% of the samples affected, respec-
tively), discovered in a larger cohort of GCB-lymphomas in the
framework of ICGC MMML-Seq (unpublished data). Two of
these latter signatures may be attributed to the action of AID; one
with a low degree of modulation by altered repair pathways and
associated with CSR (L1) and one with a high degree of mod-
ulation and associated with SHM (L2). Remarkably, the median
contribution of the signatures L1 and L2 to the overall mutations
was 30% and 21%, respectively, indicating that around 50% of all
mutations in BL are related to the B-cell speciﬁc mechanisms CSR
or SHM. Thus, we establish a link between mutational processes
active in GCB cells and BL lymphomagenesis. However, we did
not ﬁnd the patients with germline mutations to differ in the
mutational patterns of the tumor cells.
Discussion
In the present work, we used up-to-date integrated sequencing
analyze to study the mechanisms underlying Burkitt lympho-
magenesis. In depth characterization of IG-MYC breakpoint
sequences, the MYC mutations, and MYC transcripts allowed us
to reassess the mechanisms leading to generation of the IG-MYC
translocations and to identify a complex interplay of mutational,
regulatory, transcriptional, and possibly post-transcriptional
mechanisms leading to enhanced MYC activity. This very much
underscores the central role for MYC in BL pathogenesis and how
pathogenetic alterations at various levels contribute to the
deregulation of MYC activity. We also revealed a series of
mechanisms cooperating with MYC in lymphomagenesis, caused
by a wide variety of changes, including germline mutations,
somatic mutations, and structural aberrations associated with
enhancer hijacking and intron retention as well as alternative
splicing.
We have shown, that IG-MYC translocations in sBL are gen-
erated mostly via aberrant CSR or less frequently by SHM, and
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that IGHA breakpoints were almost exclusive for BL in our large
series of GCB-lymphomas. These ﬁndings extend previous tar-
geted studies using Southern blot or PCR-techniques64,65 showing
recurrent MYC translocation breakpoints in IGHA in BL and
suggesting that the cell of origin of sBL is a germinal center
experienced B-cell primed to switch to and, thus, expressing IgA.
This conclusion is also supported by the clinical observation that
sBL frequently presents in lymphatic tissue of the ileocoecal
region, i.e., one of the sites of the human body particularly
important for IgA production1,66.
The overlap of affected genes in pediatric sBL on the one hand
and in other GCB-lymphomas occurring in children like pediatric
DLBCL67 or pediatric-type FL68 on the other hand is small
(Supplementary Fig. 9). In contrast, there is a considerable
overlap with regard to genes affected in eBL despite some dif-
ferences in mutation frequencies18,69 (Supplementary Fig. 10).
Thus, although sharing a development in young children and a
derivation from germinal center B-cells, pediatric sBL, DLBCL
and FL show highly distinct pathogenesis pathways. On the other
hand, pediatric sBL and eBL, although developing in different
continents and having distinct key co-factors for their patho-
genesis (association with malaria infection of the children and
much higher frequency of tumor cell infection with EBV in eBL)
show a similar landscape of genetic lesions, and thus a closely
related pathogenesis.
Finally, despite the considerable variety in dysregulating
mechanisms the targeted pathways and complexes seem to be
rather conserved and converged on few cellular functions
including proliferation and survival, the SWI/SNF complex, and
tonic BCR signaling. This seemingly functional simplicity on the
basis of a marked aberrational complexity renders BL a good
candidate for both ex vivo modeling and in vivo targeted therapy.
Methods
Experimental model and subject details. Methods and procedures applied by the
MMML and ICGC MMML-Seq have been detailed in various publications16,19,70
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Fig. 9 Germline events and mutational signatures. a Germline mutations in genes recurrently altered by somatic mutations in BL. The affected genes are
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of the networks and are summarized in the following section. Moreover, the
experimental as well as computational procedures for the analysis of WGS and
transcriptome data are also described in the uncommitted manuscript by
Hübschmann et al., under revision.
The ICGC MMML-Seq cohort comprises pre-treatment tumor tissue and
corresponding matched normal material (peripheral blood, buffy coats
without clonal IGHV rearrangement) obtained with informed consent of the
respective patients and/or in minors their legal guardian. In addition, sorted
germinal center B-cells (GCB) and naive B-cells from non-neoplastic tonsils were
included. Both normal cell populations were obtained by ﬂow cytometry
immunophenotyping sorting (FACS) using speciﬁc markers for GCB (CD20,
CD23, CD27, and CD38) and naive B-cells (CD20hi and CD38). The ICGC
MMML-Seq study has been approved by the Institutional Review Board of the
Medical Faculty of the University of Kiel (A150/10) and of the recruiting centers.
Tumor samples were reviewed by expert hematopathologists and classiﬁed
according to the WHO 2008 guidelines. A consensus diagnosis was achieved by a
single independent microscope analysis if at least ﬁve of seven pathologists agreed
by discussion. For discrepant cases, a consensus was obtained after discussing the
respective cases at a multiheaded microscope. The immunophenotypic and
morphologic characteristics were evaluated on formalin-ﬁxed and parafﬁn-
embedded tissue sections of the diagnostic tumor biopsies. The immunophenotype
data was obtained using an immunohistochemical panel including antibodies
directed against CD20, CD10, BCL2, BCL6, and MUM1/IRF4. Lymphoma samples
were scored according to their percentage content of positive tumor cells from 0 to
4(0= 0%; 1= 1–25%; 2= 26–50%; 3= 51–75%; 4= 76–100%).
Immunohistochemical staining for Ki-67 was assessed as the percentage of positive
tumor cells on FFPE material. In addition, in situ hybridization staining for
Epstein–Barr encoding region was done in tissue sections. Moreover, in the cases
with leukemic presentation, the immunophenotype data was obtained using ﬂow
cytometry exploring the same immunophenotype markers as described above.
FISH on interphase nuclei was performed on frozen tissue sections applying the
speciﬁc probes LSI BCL6, LSI MYC, LSI IGH/MYC, CEP8 Tricolor, LSI IGH, and
LSI BCL2. All of the probes were provided by Abbott Molecular Diagnostics.
Digital image acquisition, processing, and evaluation were performed using ISIS
digital image analysis version 5.0 (MetaSystems, Altussheim, Germany). The signal
distribution was evaluated by two independent observers.
In the framework of the ICGC MMML-Seq network, we included in the present
study samples of sporadic BL in children using the following inclusion criteria:
diagnosis of BL according to the WHO 2008 criteria71, age at diagnosis ≤18 years,
presence of an IG-MYC rearrangement detected by FISH and/or WGS and absence
of chromosomal translocations affecting the BCL2 and/or BCL6 genes by FISH and
WGS, i.e., so called single hits72 (Supplementary Fig. 1a and Supplementary
Data 1). Using these criteria a total of 39 patients entered this study. Seventeen
cases were previously published16,19,70,73. All patients were registered in one of the
clinical trials of the Mature B-cell-non-Hodgkin-Lymphoma, Berlin-Frankfurt-
Münster (NHL-BFM) study group and treated according to respective protocols: 38
patients in the B-NHL BFM 04 and one in the B-NHL-BFM 95 trial74. Based on
available clinical, virological, and serological data all cases were described to be
HIV- and EBV-negative. Analysis of WGS and RNA-seq data conﬁrmed this,
except for one tumor sample showing EBV sequences by WGS (but not by RNA-
seq or EBER in situ hybridization) and one matched normal (blood) sample (but
not the corresponding tumor samples) showing traces of HIV1 virus sequences
(Supplementary Data 1).
Sample processing. The study was performed in accordance with the ICGC
guidelines (www.icgc.org). The experimental procedures for DNA and RNA
extraction, the detection and sequencing of immunoglobulin have been published
previously16,19. The tumor cell content in the cryopreserved sample material was
estimated to be at least 60% in all cases.
Sequencing. DNA libraries of the tumor and matched normal samples were
prepared using the TruSeq DNA library Preparation Kit Sets A and B (Illumina;
estimated insert size of 343 bp) or TruSeq Nano DNA library Preparation Kit
(Illumina; estimated insert size of 350 bp). Clusters were generated with cBot and
the TruSeq PE Cluster Kit v3 cBot HS (15023336_A, Illumina). Paired-end
sequencing was performed on Illumina HiSeq2000 (2x 100 bp), HiSeq2500 (2x125
bp), or Hiseq-X10 (2x 150 bp) instruments using the TruSeq SBS Kit, Version 3
(200 cycles).
RNA libraries of the tumor samples and sorted germinal center B-cells from
non-neoplastic tonsils were prepared using the TruSeq RNA library preparation Kit
Set A and B, at an insert size of ~300 bp according to manufacturer´s instructions.
Two barcoded libraries were pooled per lane and sequenced on Illumina
HiSeq2000 or HiSeq2500.
Whole-genome sequencing data processing. Read pairs were mapped to the
human reference genome (build 37, version hs37d5, (ftp://ftp.1000genomes.ebi.ac.
uk/vol1/ftp/technical/reference/phase2_reference_assembly_sequence/hs37d5.fa.
gz), using bwa-mem (version 0.7.8 with minimum base quality threshold set to zero
[-T 0] and remaining settings left at default values)75, followed by coordinate-
sorting with bamsort (with compression option set to fast (1)) and marking
duplicate read pairs with bammarkduplicates (with compression option set to best
(9)) (both part of biobambam package version 0.0.148).
Somatic SNVs and indels in matched tumor normal pairs were identiﬁed using
the DKFZ core variant calling workﬂows of the ICGC PCAWG project (https://
dockstore.org/containers/quay.io/pancancer/pcawg-dkfz-workﬂow). Initial
candidate variants for SNVs in the tumor were generated by samtools and bcftools
(version 0.1.19), followed by a lookup of the corresponding positions in the control.
To enable calling of variants with low allele frequency we disabled the Bayesian
model (by setting -p 2). Thus, all positions containing at least one high quality non-
reference base are reported as candidate variant. The resulting raw calls were
categorized into putative somatic variants and others (artifacts, germline) based on
the presence of variant reads in the matched normal sample. The frequency of all
putative somatic variants was then reﬁned by checking for potential redundant
information due to overlapping reads and precise base counts for each strand were
determined. All variants were annotated with dbSNP141, 1000 Genomes (phase 1),
Gencode Mapability track, UCSC High Seq Depth track, UCSC Simple-Tandem
repeats, UCSC Repeat-Masker, DUKE-Excluded, DAC-Blacklist, UCSC Selfchain.
The conﬁdence for each variant was then determined by a heuristic punishment
scheme taking the aforementioned tracks into account. In addition variants with
strong read biases according to the strand bias ﬁlter were removed. High-
conﬁdence variants were used for further analysis. To identify indel events tumor
and matched control samples were analyzed by Platypus76 (version 0.8.1). All
variants indicating an indel were categorized into putative somatic and other based
on the genotype likelihoods (matched genotype 0/0 for somatic indels). High-
conﬁdence somatic variants were required to either have the Platypus ﬁlter ﬂag
PASS or pass custom ﬁlters allowing for low variant frequency using a scoring
scheme. Candidates with the badReads ﬂag, alleleBias, or strandBias were discarded
if the variant allele frequency was <10%. Additionally, combinations of Platypus
non-PASS ﬁlter ﬂags, bad quality values, low genotype quality, very-low variant
counts in the tumor, and presence of variant reads in the control were not
tolerated. In order to remove recurrent artifacts and misclassiﬁed germline events,
somatic indels that were identiﬁed as germline in at least two patients in the ICGC
MMML-seq cohort were excluded. For two samples (4152036, 4178518) tumors
and their matched controls were sequenced on different Illumina instruments
(Hiseq2500 and HiseqX). To prevent technology-speciﬁc artefacts, the standard
SNV and indel calling workﬂow was extended with ﬁlters developed for samples
without matched control. To this end, variants recorded in dbSNP version 14777
with “COMMON = 1” tag were removed, but rescued if they had a corresponding
OMIM record in dbSNP. We additionally removed mutations found in ExAC
version 0.3.1 (>0.1%; Lek et al., 2016), EVS (>1%; Exome Variant Server, NHLBI
Exome Sequencing Project (ESP)) and our control dataset (>2%, among 280
controls). Somatic small variants in these samples were further ﬁltered out if their
respective position was covered insufﬁciently in the control sample (<20X) or if the
fraction of variant reads in the control was too high (>1/30).
For some samples (4100314, 4103570, 4163741, 4170844, 4190231, 4190316)
increased SNV artefact rates were detected, which were related to higher base
quality scores for wrongly called bases. For these samples the base quality threshold
was increased from 13 to 20 and low mutant allele frequency (MAF) penalty was
switched off (i.MPILEUP_OPTS="-REI -Q 20 -q 30 -ug";
CONFIDENCE_OPTS=" -c 0 -l 1").
SNVs and indels were annotated using ANNOVAR78 according to GENCODE
gene annotation (version 19) and overlapped with variants from dbSNP (build 141)
and the 1000 Genomes Project database. SNVs classiﬁed as splicing, nonand
accurate short read alignment with Burrowssynonymous changes, stop-gains, and
stop-losses were predicted to affect protein function.
Detection of copy number alterations and allelic imbalances. Allele-speciﬁc
copy number alterations were detected using ACEseq (allele-speciﬁc copy number
estimation from whole-genome sequencing; unpublished data).
ACEseq determines absolute allele-speciﬁc copy numbers as well as tumor
ploidy and tumor cell content based on coverage ratios of tumor and control as
well as the B-allele frequency (BAF) of heterozygous single-nucleotide
polymorphisms (SNPs). SVs called by SOPHIA were incorporated to improve
genome segmentation.
Ploidies were manually checked and compared with FISH results. Adjustments
were made if necessary. Accordingly, tumor cell content estimates were compared
to the doubled median MAF and adjusted in case ACEseq and MAF-based
estimates deviated by more than 10% from each other.
Final copy number segments were further smoothed to calculate the total
number of gains and losses. Neighboring segments were merged if they rounded to
the same copy number and deviated by less than 0.5 copies in case of segments <20
kb or deviated by less than 0.3 copies otherwise. Remaining segments <500 kb were
merged with their closer neighbor based on allele-speciﬁc and total copy number
and once again segments smaller than 2Mb deviating by less than 0.4 copies were
merged. Based on the resulting segments the number of gains and losses was
estimated.
Furthermore, the fraction of aberrant genome was estimated corresponding to
the fraction of the genome that is classiﬁed either as duplication or deletion (>0.7
deviation from the ploidy) or was identiﬁed as a loss of heterozygosity.
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Detection of genomic structural rearrangements. SV were called using the
SOPHIA algorithm (unpublished data). The source code of SOPHIA is available at
https://bitbucket.org/utoprak/sophia/. Brieﬂy, SOPHIA uses supplementary align-
ments as produced by bwa-mem as indicators of a possible underlying SV. SV
candidates are ﬁltered by comparing them to a background control set of
sequencing data obtained using normal blood samples from a background popu-
lation database of 3261 patients from published TCGA and ICGC studies and both
published and unpublished DKFZ studies, sequenced using Illumina HiSeq 2000,
2500 (100 bp), and HiSeq X (151 bp) platforms and aligned uniformly using the
same workﬂow as in this study. An SV candidate is discarded if (i) it has more than
85% of read support from low quality reads; (ii) the second breakpoint of the SV
was unmappable in the sample and the ﬁrst breakpoint was detected in 10 or more
background control samples; (iii) an SV with two identiﬁed breakpoints had one
breakpoint present in at least 98 control samples (3% of the control samples); or
(iv) both breakpoints have less than 5% read support. SVs aberrations with scores
from 3 to 5 were used for all the analysis, with the exception of IG translocations.
Moreover, for the detection of the hallmark event in BL, the IG-MYC
translocation, the DELLY79 algorithm was used in addition. We used DELLY v0.5.9
to call simple and complex structural variants (SVs). A high conﬁdent set of
somatic SVs of size >1 kb, supported by at least four read pairs, and ﬁltered for
absence in the paired normal control tissue was derived. Additionally, we removed
SVs detected either in ≥1% of a set of 1105 germline samples from healthy
individuals from the 1000 Genomes Project phase I or in the panel of normal
samples constructed from the DELLY’s consensus germline SVs called in PCAWG
normal tissues sample.
Replication timing. Repli-Seq scores80 were used to investigate the replication
timing of mutations. Replication timing of lymphoblastoid cell lines was calculated
as median Repli-Seq score of the lymphoblastoid ENCODE cell lines GM12801,
GM06990, GM12812, GM12813, and GM12878.
Detection of mutational signatures. Unsupervised analysis of mutational sig-
natures. An unsupervised analysis of mutational signatures based on non-negative
matrix factorization (NMF) was performed on a larger cohort of 219 germinal
center derived B-cell lymphomas in the framework of ICGC MMML-Seq
(unpublished data). This unsupervised method has high requirements on statistical
power, i.e., the number of samples and the average mutational load per sample in
the input data, and application only to the BL subcohort presented in this
manuscript would not have yielded stable and reliable patterns. NMF was run
using the function runNmfGpu from the R software package Bratwurst (unpub-
lished data), which provides wrapper functions for NMF solvers on graphical
processing units (GPUs) using the Compute Uniﬁed Device Architecture (CUDA)
8 framework and the cudamat library. The factorization rank was varied from 2 to
15. The optimal factorization rank was obtained by simultaneously minimizing the
Frobenius error, maximizing the cophenetic correlation coefﬁcient and minimizing
the Amari distance. For every factorization rank, 500 iterations over different
random initializations were performed. For every initial condition, iteration over
update equations was performed at most 10000 times.
Supervised analysis of mutational signatures. Supervised analysis of mutational
signatures has been performed using the R package YAPSA (unpublished data).
Using YAPSA, a linear combination decomposition of the mutational catalog with
known and predeﬁned signatures was computed with the function LCD complex
cutoff by non-negative least squares (NNLS) using functions implemented in the R
package lsei78. In order to increase speciﬁcity, LCD complex cutoff applies the
NNLS algorithm twice: once proposing all signatures supplied by the user to the
decomposition, and then after the ﬁrst execution, only those signatures whose
exposures, i.e., contributions in the linear combination, were higher than a certain
cutoff, were kept and the NNLS was run again with the reduced set of signatures.
As detectability of the different signatures may vary, the cutoffs were chosen to be
signature-speciﬁc. The signature-speciﬁc cutoffs were determined in a random
operator characteristic (ROC) analysis using publicly available data on mutational
catalogs of 7042 cancers (507 from whole-genome sequencing and 6535 from
whole exome sequencing)81 and mutational signatures from the COSMIC database
[http://cancer.sanger.ac.uk/cosmic/signatures], downloaded on January 15th, 2016.
The following cut-offs were employed - AC1: 0;AC2: 0.01045942; AC3: 0.08194056;
AC4: 0.01753969; AC5: 0; AC6: 0.001548535; AC7: 0.04013304; AC8: 0.242755;
AC9: 0.1151714; AC10: 0.01008376; AC11: 0.09924884; AC12: 0.2106201; AC13:
0.007876626; AC14: 0.1443059; AC15: 0.03796027; AC16: 0.3674349; AC17:
0.002647962; AC18: 0.3325386; AC19: 0.1167454; AC20: 0.1235028; AC21:
0.1640255; AC22: 0.03102216; AC23: 0.03338659; AC24: 0.03240176; AC25:
0.01611908; AC26: 0.09335221; AC27: 0.009320062; AC28: 0.05616434; AC29:
0.05936213; AC30: 0.05915355.
Detection of oncodrivers. IntoGen (version 3.0.5)39 was run with default settings
on all somatic SNVs and indels to identify drivers amongst the 39 BL.
Integration of different variant types. SNVs, indels, SVs, and CNAs were inte-
grated to account for all variant types in the recurrence analysis. Whilst all genes
with SNVs or indels in coding regions (nonsynonymous, splicing, frameshift event)
and ncRNA were included, SVs and CNAs were handled differently. Any genes
between the breakpoints of focal SVs (<1Mbp) were considered. However,
duplications and deletions called by SOPHIA in the range of 10 kbp and 1Mbp had
to be veriﬁed by ACEseq, discarding subclonal events with less than 0.7 copy
number deviation from the average ploidy. For larger SVs only genes that were
directly hit by a breakpoint were considered. Only focal CNA events (<1Mbp)
were taken into account for variant integration, as these are more likely to target
speciﬁc genes within the affected region than large events such as whole chro-
mosome arm events. To capture the precise target focal SVs and CNAs were
combined and local maxima of overlapping regions with more than one event were
identiﬁed.
Finally, genes affected by SNVs, indels, focal, and large SVs or genes within the
CNA regions of interest were considered for the recurrence analysis and any gene
affected ≥3 times was further looked up in the remaining focal CNA regions and
added to the oncoprints.
Analysis at hotspots of somatic hypermutation machinery. Mutations in the
genome region of the MYC gene (chr8: 128748330–128753680 bp, hg19) were
analyzed for targeting the RGYW and DGYW motifs. Expected values were cal-
culated by dividing the number of bases overlapping the motif by the number of all
bases in the region and multiplying with the total number of mutations (coding
and non-coding) observed and by dividing the number of G/C exchanges in the
motif by the number of all G/C exchanges in the region and multiplying with the
total number of mutations (non-mutations) observed at G/C positions. For sta-
tistical analysis Fisher’s exact test was done.
MYC mutation analysis at phosphorylation regions. Mutations in exon 2 of
MYC were analyzed for enrichment in the phosphorylation area, considering a
window of −/+ 4 amino acids close to a phosphorylation residue. The frequency of
mutations observed in phosphorylation windows was obtained by dividing the
observed number of mutations in phosphorylation windows (n= 20) through its
length (n= 78), while the expected frequency was determined by dividing the total
number of mutations in exon 2 (n= 31) through its length (n= 252). For statistical
analysis, the Fisher´s exact test was used.
Detection of germline mutations. We employed freebayes (v1.1.0) (https://github.
com/ekg/freebayes) in single sample- and paired-sample calling mode for discovery
of single-nucleotide variants, multi nucleotide variants, and insertions/deletions
<50 bp (used parameters: --min-repeat-entropy 1, --report-genotype-likelihood-
max, --alternate-fraction 0.2, and --no-partial-observations). Raw variant predic-
tions were further ﬁltered for quality (QUAL>20, QUAL/AO>2), strand bias
artifacts (SAF>1, SAR>1), read position artifacts (RPR>1, RPL>1), and normalized
for consistent representation across patients with vt (v0.5) (https://genome.sph.
umich.edu/wiki/Vt). Germline variants were annotated with the Ensembl Variant
Effect Predictor (VEP) (r81, https://www.ensembl.org/info/docs/tools/vep/index.
html). High impact (i.e., damaging) germline mutations were deﬁned as frameshift,
stop gain, start lost, canonical splice site, and known pathogenic non-canonical
splice site variants (ClinVar; accessed 2017–02–16). Putative damaging germline
mutations were removed if the estimated minor allele frequency (MAF) in at least
one continental population was above 0.5%, which we judged based on
53,105 sequenced individuals that were assigned to known (control) populations
and without cancer diagnosis from the ExAC resource (http://exac.broadinstitute.
org), the 1000 Genomes Project (http://www.internationalgenome.org), and the
NHLBI GO Exome Sequencing Project. Putative gain-of-function (GoF) missense
variants in TP53 were further evaluated based on information in the IARC TP53
database (http://p53.iarc.fr/) and annotated as pathogenic if TP53 mutations were
classiﬁed as “non-functional” based on experimental transcriptional activity assays.
Finally, all germline mutations were excluded from the analysis if annotated as
benign in ClinVar.
For the detection of germline mutations in genes typically somatically mutated
in the BL cohort, we additionally identiﬁed candidate germline variants using the
following criteria: (i) variant has a combined annotation dependent depletion
(CAAD) score higher than 13, which is considered high impact variants; (ii) for a
missense variant, gene’s ExAC missense intolerance Z-score higher than 2 or, for
an LoF variant, the gene’s ExAC pLI score higher than 0.9; (iii) the variant was not
observed in 184 non-BL gcBCL cases available locally (Huebschmann et a., under
revision).
Telomere content estimation. The telomere content was determined from whole-
genome sequencing data using the software tool TelomereHunter (www.dkfz.de/
en/applied-bioinformatics/telomerehunter/telomerehunter.html) (unpublished
data). In short, unmapped reads or reads with a very low alignment conﬁdence
(mapping quality lower than 8) containing six non-consecutive instances of the
four most common telomeric repeat types (TTAGGG, TCAGGG, TGAGGG, and
TTGGGG) were extracted. The telomere content was determined by normalizing
the telomere read count to all reads in the sample with a GC-content of 48–52%. In
the case of tumor samples, the telomere content was further corrected for the
tumor purity (as estimated by ACEseq) using the following formula:
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Tpure ¼ TC 1purityð Þpurity Where T and C are the telomere contents of the tumor and
control sample, respectively, and Tpure is the purity-corrected telomere content of
the tumor sample.
Transcriptome analysis. Transcriptome data were mapped with segemehl
0.2.0, 82 allowing for spliced alignments and using a minimum accuracy of
90%. Gene expression values were counted using RNAcounter 1.5.2 [https://
pypi.python.org/pypi/rnacounter], using the “--nh” option and counting only
exonic reads (-t exon). Differential expression was analyzed using EdgeR with
default parameters and a signiﬁcance criterion of 0.05 (p-value adjusted for
multiple testing)83.
Gene expression based BL classiﬁcation. We transferred an array-based gene
expression classiﬁer by Hummel et al.21 to distinguish mBL and non-mBL using
RNA-seq data. In short: we considered all unique genes represented by Affymetrix
probe sets included in the original classiﬁer that were available in the RNA-seq data
(37 upregulated in BL; 14 downregulated in BL). An initial set of 48 solid lymphoma
samples was classiﬁed based on histopathology and FISH into BL and DLBCL. For
these cases, RNA-seq data for the exemplarily selected regions was analyzed on the
average reads per million (RPM) scale. Expression values were log transformed and
standardized. Unsupervised hierarchical clustering resulted in a perfect separation
of histopathologically deﬁned BL and DLBCL as well as up- and downregulated
probe sets. We utilized the classiﬁcation based on histopathology to estimate the
density of expression values separately for BL and DLBCL samples assuming normal
distribution of expression values for each probe set in each subgroup. For classiﬁ-
cation, the conditional probability for BL is estimated based on the observed
expression and the estimated subgroup speciﬁc distributions. We applied the
median of the estimated BL probabilities over all exemplarily selected regions as an
overall classiﬁcation score for BL vs DLBCL. Given the results of the testset with 48
histopathologically classiﬁed lymphomas we applied the thresholds of <0.25 for
non-mBL and ≥0.66 for mBL. Despite being developed for solid BL, we also applied
the RNA-seq based classiﬁer to leukBL and compared to 13 prototypic non-BL cases
(DLBCL) from the ICGC MMML-seq cohort (Supplementary Fig. 1b).
Fusion transcripts analysis. For all the fusion genes detected by WGS, we checked
the presence of fusion transcripts by usage of two different tools, segemehl and
confuse. To deﬁne the presence of fusion transcripts the junction of the fusion
transcripts detected by both tools were used. Segemehl is a splice-aware mapper
that can detect reads with splice sites independent of annotation. Segemehl
alignment ﬁles were searched for reads that originated in the vicinity of one of the
genes containing the break point and were spliced to the vicinity of the other gene,
with a maximum distance to the gene of 20k bases. If a sufﬁcient amount of spliced
reads (above 3) were found, all other ICGC MMML-Seq RNA-seq alignment ﬁles
were checked for existence of the respective splice site. Only splice sites that were
unique to the dataset containing the break point were reported.
ConFuse is a novel downstream ﬁltering tool for reliably selecting high-
conﬁdence fusion candidates. It takes multiples features into account to assign each
fusion transcript a conﬁdence score84. These features are mainly related to
mapping artifact, mapping quality, number of supporting reads (spanning reads
and split reads), and structural motifs. ConFuse classiﬁes the fusion transcripts into
three categories (high-, medium- and low-conﬁdence) based on the conﬁdence
score. It can prioritize the fusion candidates for further analysis and experimental
validation.
Differential alternative splicing analysis. Differential splicing analysis was
conducted using DIEGO85, with default parameters and a signiﬁcance criterion of
0.05 (adjusted p-value).
PCR and Sanger sequencing. Selected SNVs and SVs were ampliﬁed by poly-
merase chain reaction from the genomic DNA using speciﬁc primers. Amplicons
were puriﬁed (MinElute 96 UF PCR Puriﬁcation Kit, Qiagen, Hilden, Germany)
and cycle-sequenced using ﬂuorescent dye-termination (Big Dye Terminator V1.1
Cycle Sequencing Kit, Applied Biosystems, Darmstadt, Germany) and an ABI 3100
or ABI 310 automatic capillary genetic analyzer.
In addition, a subset of fusion transcripts were validated using speciﬁc primers
to amplify breakpoint fusion sequence. The RNAs from the tumor samples were
treated with DNase I (RNAase-Free, Ambion, Thermoﬁsher Scientiﬁc, Darmstadt,
Germany). Complementary DNA (cDNA) was synthesized from 1 μg of total RNA
using Quanti Tect Reverse Transcription kit (Qiagene, Hilden, Germany)
according to manufacturer´s instruction. The cDNAs were ampliﬁed by
polymerase chain reaction using speciﬁc primers and conditions and the amplicons
were puriﬁed and sequenced according to the conditions described above.
TCF3-ID3-CBFA2T3 interaction modeling. We modeled the TCF3-ID3 dimer
using Modeller86 and the ternary complex structure between the Tcf3-Neurod1
dimer and DNA (PDB ID: 2QL2) as a template. The TCF3-CBFA2T3 interaction
interface was predicted using Interprets87 and the structure between TCF12-
RUNX1T1 (PDB ID: 2KNH) as a template. Electrostatic surfaces for the ID3-TCF3
dimers (considering both E12 and E47 isoforms) were calculated through the APBS
approach available in Pymol.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
WGS and RNA-Seq alignments are available from the European Genome-phenome
archive (EGA) under the accession numbers: EGA-S00001002198 & EGAS00001001692.
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